EKSDX | HBLYX | EKSDX / HBLYX | |
Total Expense Ratio | 0.88 | 0.67 | 131% |
Annual Report Gross Expense Ratio | 1.12 | 0.67 | 167% |
Fund Existence | 15 years | 19 years | - |
Gain YTD | -2.766 | -2.722 | 102% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 250000 | 400% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 323M | 11.3B | 3% |
Annual Yield % from dividends | 5.80 | 3.53 | 164% |
Returns for 1 year | 3.22 | -1.50 | -214% |
Returns for 3 years | 11.64 | -0.31 | -3,768% |
Returns for 5 years | 31.15 | 14.76 | 211% |
Returns for 10 years | 35.92 | 28.95 | 124% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FDFF | 33.41 | 3.01 | +9.90% |
Fidelity Disruptive Finance ETF | |||
CVLC | 67.09 | 6.00 | +9.82% |
Calvert US Large-Cp Cor Rspnb ETF | |||
HYT | 9.25 | 0.78 | +9.21% |
Blackrock Corporate High Yield Fund | |||
XPH | 38.86 | 2.04 | +5.54% |
SPDR® S&P Pharmaceuticals ETF | |||
RNWZ | 21.34 | N/A | N/A |
TrueShares Eagle Glbl Rnwbls Engy IncETF |